Exscientia

AI for accelerated drug discovery

Oxford, United Kingdom

Exscientia is an AI-driven drug design and development company, founded in 2012, pioneering precision medicine to discover new therapies faster. It uses AI throughout the drug discovery cycle, including in silico design and automated robots, and was the first AI company to have designed a novel molecule for clinical trials.

Shareable draft

Check out Exscientia on @MedStartr Today Exscientia is an AI-driven drug design and development company, founded in 2012, pioneering precision medicine to discover new therapies faster. It uses AI throughout the drug discovery cycle, including in silico design and automated robots, and was the first AI company to have designed a novel molecule for clinical trials. #CDK7 #LSD1 #Immunology #Neuroinflammation #InflammatoryConditions #AutoImmuneConditions #Psychiatry #AntiviralDevelopment #RareDiseases #CancerOncology #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/gvLjpYzd2xU

Get Involved in Exscientia

How We Help

Problem Statement

Exscientia aims to disrupt traditional drug discovery pipelines, which are often characterized by high costs, long timelines, and high failure rates, by introducing an efficient, AI-driven approach.

Core Technology

generative artificial intelligence (AI) to discover new therapies

Key Differentiators

first AI company to have designed a novel molecule that entered clinical trials; accelerate drug design by up to 70%; decrease capital costs by 80%

Clinical Focus

Exscientia's internal pipeline is primarily focused on oncology. Through partnerships, its reach extends to immunology, neuroinflammation, inflammatory and auto-immune conditions, psychiatry, rare diseases, and the development of broad-spectrum antivirals.

Target Customers

Major pharmaceutical companies

Product Stage

Beta

Company Info

Business Model: Exscientia operates with a "full-stack" AI drug discovery model, developing its proprietary pipeline and forming collaborations with major pharmaceutical companies. It generates revenue through upfront payments, milestone payments, and potential royalties from these partnerships.
Founded: 2012
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.exscientia.ai

Disease Areas

CDK7 LSD1 Immunology Neuroinflammation Inflammatory Conditions Auto-Immune Conditions Psychiatry Antiviral Development Rare Diseases Cancer & Oncology

Technologies

Drug DesignAutomated RobotsIn Silico DesignGenerative AIPrecision Medicine TechPharmatechDrug Discovery PlatformAutomated RoboticsBiophysical AnalysisHuman Tissue TestingAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

Aims to bring novel compounds to clinical entry in 12 to 18 months. Integrates human tissue testing for drug candidates.

🌐Website

MedStartr Engagement Score

Too Big!

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Exscientia?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.